Researchers wanted to find out if ivermectin compared to placebo shortened symptom duration for adult patients in the United States with symptomatic mild to moderate COVID-19. According to results of the randomized clinical trial published in JAMA on October 21, 2022, the research team found that among outpatients with mild to moderate COVID-19, treatment with ivermectin compared with placebo did not significantly improve time to recovery

New CDC findings highlight the hidden dangers of antihistamines for users who have concomitant exposure to opioids.

Clinicians treating patients with COVID-19  who are at risk for progression to acute disease should be aware of potential drug–drug interactions when the oral antiviral treatment nirmatrelvir/ritonavir (Paxlovid—Pfizer) is administered to people taking common cardiovascular drugs, experts warn in a new Journal of the American College of Cardiology article.

A recent survey from the Institute for Safe Medication Practices (ISMP) puts the pharmacist’s role during code situations into focus.

Compared with more than 3 million unexposed pregnancies, antidepressant-exposed pregnancies could not be directly correlated to a higher risk of autism spectrum disorder, ADHD, learning or developmental speech/language disorders, developmental coordination disorder, intellectual disability, or behavioral disorders, according to new research published in JAMA Internal Medicine.